CompletedNot Applicable

An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol

South Korea3,907 participantsStarted 2017-11-06

Plain-language summary

This study examines quality of life and patient satisfaction in postmenopausal women receiving raloxifene to prevent/treat osteoporosis, and vitamin D to reduce risk of fracture using clinical practice data. The purpose of this study is to observe quality of life(QOL), medication compliance and patient satisfaction who got combination therapy with raloxifene/cholecalciferol (raloxifene 60mg + cholecalciferol 800 IU, Rabone D®, Hanmi Pharma, South Korea) for 6 months.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Postmenopausal women who need to prevent/treat osteoporosis * Subject who got raloxifene/cholecalciferol combination therapy prescription with confirmation by the investigator's medical decision * Subjects who can consent voluntarily Exclusion Criteria: * Patients for whom use of raloxifene/cholecalciferol combination therapy is prohibited * Pregnant women, nursing women or child-bearing aged females deemed capable of pregnancy

What they're measuring

The EuroQol EQ-5D

Timeframe: 6 months

Trial details

NCT IDNCT04788290

SponsorHanmi Pharmaceutical Company Limited

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-07-13

View on ClinicalTrials.gov More Osteoporosis trials